RT Journal Article
SR Electronic
T1 ENHANCING VENTRICULAR TACHYCARDIA ABLATION OUTCOMES: THE IMPACT OF FUNCTIONAL MAPPING IN CHAGAS CARDIOMYOPATHY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.08.24302420
DO 10.1101/2024.02.08.24302420
A1 Wilnes, Bruno
A1 Castello-Branco, Beatriz
A1 de Araújo Silva, Gustavo
A1 Mayrink, Marina Pereira
A1 da Silva, José Luiz Padilha
A1 Barbosa, Marco Paulo Tomaz
A1 França, Anna Terra
A1 França, Marcos Roberto Queiroz
A1 de Araújo, Crizianne Rodrigues Santos
A1 de Miranda, Reynaldo Castro
A1 Ribeiro, Antonio Luiz Pinho
A1 do Carmo Pereira Nunes, Maria
A1 do Carmo, André Assis Lopes
YR 2024
UL http://medrxiv.org/content/early/2024/02/09/2024.02.08.24302420.abstract
AB Background: Chagas cardiomyopathy presents a significant public health challenge in Latin America, marked by high rates of ventricular tachycardia (VT) and implantable cardioverter-defibrillator (ICD) interventions. This study explores the efficacy of functional mapping strategies in VT ablation for Chagas cardiomyopathy compared to conventional voltage map-based approaches. Methods: This observational study, involving 66 patients, employed electroanatomic mapping for both epicardial and endocardial regions. In voltage-based mapping (group 1), all patients underwent bipolar substrate mapping with standard scar settings for epicardial and endocardial regions, while functional mapping (group 2) was obtained using a single ventricular extra-stimulus with Late Potential and Isochronal Late Activation Maps associated with annotation of decremental and blocked electrograms. The primary endpoint was post-ablation VT recurrence over a 30-month follow-up. Results: Voltage-based and functional mapping groups presented 42 and 24 patients, respectively. When compared to the voltage-based mapping strategy, functional mapping-assisted procedures were associated with lower post-ablation VT recurrence on Kaplan-Meier’s log-rank test (P=0.045). After multivariate analysis, functional mapping independently associated with a 90.3% reduction in the risk of 30-month VT recurrence (HR: 0.097, 95% CI: 0.012-0.760, P=0.026) compared to voltage-based mapping. Conclusion: Functional mapping in Chagas cardiomyopathy VT ablation is associated with significantly reduced recurrence rates, emphasizing its potential as an effective strategy in this challenging condition. This study provides valuable insights for improving VT ablation outcomes. However, there is a dire need for a large-scale randomized controlled trial to generate high-quality evidence in this field.What Is Known 1) Functional mapping holds the potential advantage of identifying substrate situated within normal voltage areas, but there is no direct comparison between functional mapping and conventional voltage map-based strategy.2) Chagas cardiomyopathy, a highly arrhythmogenic disease, is linked to higher rates of post-ablation ventricular tachycardia (VT) recurrences and poor overall prognosis.What The Study Adds 1) After adjusting for confounding predictors, a functional map-based strategy showed a 90.3% reduction in post-ablation VT recurrence over a 30-month follow-up period.2) In 26.8% of patients with Chagas cardiomyopathy referred for VT ablation, a periaortic substrate was identified—a location not previously documented in this condition; poor mapping of this region may contribute to ablation failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr Ribeiro is supported in part by CNPq (310790/2021-2 and 465518/2014-1) and by FAPEMIG (PPM-00428-17 and RED-00081-16). Dr Nunes is supported in part by CNPq (308288/2020-3). The other authors declare to have received no funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Federal University of Minas Gerais gave ethical approval for this work under the protocol number 0682020300011.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAvailability of data and material: The datasets generated and analyzed during the current study are not publicly available due to privacy and ethical considerations. However, de-identified data may be made available from the corresponding author upon reasonable request and approval from the institutional review board. Code availability: The specific algorithms, codes, and software used in data analysis and interpretation are available from the corresponding author upon reasonable request. The authors are committed to transparency and reproducibility, providing necessary information for verification and further research.